Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.

Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A, Davies FE, Ross FM, Morgan GJ.

Blood. 2011 Jan 13;117(2):553-62. doi: 10.1182/blood-2010-04-279539. Epub 2010 Oct 13.

2.

DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors.

Salhia B, Baker A, Ahmann G, Auclair D, Fonseca R, Carpten J.

Cancer Res. 2010 Sep 1;70(17):6934-44. doi: 10.1158/0008-5472.CAN-10-0282. Epub 2010 Aug 24.

3.

Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.

Schmidt-Hieber M, Gutiérrez ML, Pérez-Andrés M, Paiva B, Rasillo A, Tabernero MD, Sayagués JM, Lopez A, Bárcena P, Sanchez ML, Gutiérrez NC, San Miguel JF, Orfao A.

Haematologica. 2013 Feb;98(2):279-87. doi: 10.3324/haematol.2011.060632. Epub 2012 Aug 28.

4.

The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.

An G, Li Z, Tai YT, Acharya C, Li Q, Qin X, Yi S, Xu Y, Feng X, Li C, Zhao J, Shi L, Zang M, Deng S, Sui W, Hao M, Zou D, Zhao Y, Qi J, Cheng T, Ru K, Wang J, Anderson KC, Qiu L.

Clin Cancer Res. 2015 May 1;21(9):2148-56. doi: 10.1158/1078-0432.CCR-14-2576. Epub 2015 Feb 4.

5.

Treatment of multiple myeloma: 2009 update.

[No authors listed]

Prescrire Int. 2009 Dec;18(104):263-6.

PMID:
20025098
6.

[Chemotherapy for multiple myeloma].

Ishida T.

Nihon Rinsho. 2007 Dec;65(12):2280-4. Review. Japanese.

PMID:
18069273
7.

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results.

Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, Cook G, Feyler S, Johnson PR, Rudin C, Drayson MT, Owen RG, Ross FM, Russell NH, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group..

Haematologica. 2012 Mar;97(3):442-50. doi: 10.3324/haematol.2011.043372. Epub 2011 Nov 4.

8.

Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.

Mailankody S, Mena E, Yuan CM, Balakumaran A, Kuehl WM, Landgren O.

Leuk Lymphoma. 2010 Dec;51(12):2159-70. doi: 10.3109/10428194.2010.525725. Epub 2010 Oct 20. Review.

PMID:
20958231
9.

Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.

Vogl DT, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Perl A, Loren AW, Goldstein SC, Nasta SD, Andreadis C, Mangan PA, Hummel K, Siegel DL, Glatstein E, Stadtmauer EA.

Am J Hematol. 2007 Dec;82(12):1071-5.

10.

Treatment strategies for plasma cell myeloma.

Smith L, Alexanian R.

CA Cancer J Clin. 1985 Jul-Aug;35(4):214-20. No abstract available.

11.

Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.

Zou D, An G, Zhu G, Wang J, Shi L, Meng H, Xu Y, Sui W, Deng S, Zhan F, Qiu L.

Biol Blood Marrow Transplant. 2014 Mar;20(3):319-25. doi: 10.1016/j.bbmt.2013.11.022. Epub 2013 Dec 1.

12.

[New treatment strategies for multiple myeloma].

Ozaki S.

Rinsho Ketsueki. 2009 Oct;50(10):1506-17. Review. Japanese. No abstract available.

PMID:
19915360
13.

The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agents.

Kuroda Y, Sakai A, Okikawa Y, Munemasa S, Katayama Y, Hyodo H, Imagawa J, Takimoto Y, Okita H, Ohtaki M, Kimura A.

Int J Hematol. 2005 May;81(4):335-41.

PMID:
15914366
14.
15.

Biology and therapy of multiple myeloma.

Barlogie B, Alexanian R.

Acta Haematol. 1987;78 Suppl 1:171-4.

PMID:
3124442
16.

[Heterogenicity of the response to chemotherapy in plasmablastic myeloma].

Paule B, Quillard J, Bisson M, Massias P.

Nouv Rev Fr Hematol. 1987;29(6):391-6. French.

PMID:
2454453
17.

Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma.

Greenberg AJ, Cousin M, Kumar S, Ketterling RP, Knudson RA, Larson D, Colby C, Scott C, Vachon CM, Rajkumar SV.

Eur J Haematol. 2013 Sep;91(3):193-5. doi: 10.1111/ejh.12133. Epub 2013 Jul 22.

18.

Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients.

Brousseau M, Leleu X, Gerard J, Gastinne T, Godon A, Genevieve F, Dib M, Lai JL, Facon T, Zandecki M; Intergroupe Francophone du Myélome..

Clin Cancer Res. 2007 Oct 15;13(20):6026-31.

19.

Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.

Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Zangari M, Dhodapkar M, Shaughnessy JD Jr.

Blood. 2007 Feb 15;109(4):1692-700. Epub 2006 Oct 5.

20.

A case of multiple myeloma with nuclear hypersegmentation after MP/VAD/VCAP-IFN therapies with a good prognosis.

Nara M, Suzuki K, Inoue Y, Enomoto H, Saito T, Fujioka S.

Acta Haematol. 1993;90(2):102-3. No abstract available.

PMID:
8285014

Supplemental Content

Support Center